Page 335 - Read Online

Page 6 of 8 Lancaster et al. Vessel Plus 2019;3:34 I http://dx.doi.org/10.20517/2574-1209.2019.16

DECLARATIONS
Authors’ contributions
Conception, design, analysis and interpretation of the data: Lancaster JJ, Koevary JW, Chinyere IR,
Daugherty SL, Fox KA, Goldman S
All the authors made substantial contributions to this article.

Availability of data and materials
Not applicable.

Financial support and sponsorship
This was supported by grants from The WARMER Foundation, the Department of Veterans Affairs,
University of Arizona, Sarver Heart Center, The Martin and Carol Reid Family Charitable Remainder
Trust and the NHLBI (T32 HL007249-43).

Conflicts of interest
Drs. Lancaster, Koevary, Goldman and Ms. Daugherty have a financial interest in Avery Therapeutics, a
biotechnology company that is commercializing platform technologies to deliver cell-based therapies for
clinical use. The other authors (Chinyere IR, Fox KA) report no conflicts.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, et al. Embryonic stem cell lines derived from human
blastocysts Science 1998;282:1145-7.
2. Yu J, Vodyanik M, Smuga-Otto K, Frane J, Antosiewicz-Bourget J, et al. Induced pluripotent stem cell lines derived from human
somatic cells. Science 2007;318:1917-20.
3. Davis J, Davis C, Correll RN, Makarewich CA, Schwanekamp JA, et al. Tension-Based Model Distinguishes Hypertrophic versus
Dilated Cardiomyopathy. Cell 2016;165:1147-59.
4. Eschenhagen T, Carrier L. Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytes-a systematic
review. Pflugers Arch 2019;471:755-68.
5. Tanaka A, Yuasa S, Node K, Fukuda K. Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells. Int
J Mol Sci 2015;16:18894-22.
6. Wang Y, Liang P, Lan F, Wu H, Lisooski L, et al. Genome Editing of Isogenic Human Induced Pluripotent Stem Cells Recapitulates
Long QT Phenotype for Drug Testing. J Am Coll Cardiol 2014:64;451-9.
7. Mummery CL. Perspectives on the Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Biomedical Research.
Stem Cell Rep 2018;11:1306-11.
8. Stillitano F, Hansen J, Kong CW, Karakikes I, Funck-Brentano C, et al. Modeling susceptibility to drug-induced long QT with a panel
of subject-specific induced pluripotent stem cells. Elife 2017;6:e19406.
9. Menasche P, Hagège AA, Vilquin JT, Desnos M, Abergel E, et al. Autologous skeletal myoblast transplantation for severe
postinfarction left ventricular dysfunction. J Am Coll Cardiol 2003:41;1078-83.
10. Fisher SA, Doree C, Mathur A, Martin-Rendon E. Meta-Analysis of Cell Therapy Trials for Patients with Heart Failure - An Update.
Circ Res 2015;116:1361-77.
11. Nguyen PK, Rhee JW, Wu JC. Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review. JAMA Cardiol 2016;1:831-41.
12. Muller-Ehmsen J, Whittaker P, Kloner RA, Dow JS, Sakoda T, et al. Survival and development of neonatal rat cardiomyocytes
transplanted into adult myocardium. J Mol Cell Cardiol 2002;34:107-16.
13. Leor J, Amsalem JY, Cohen S. Cells, Scaffolds, and molecules for myocardial tissue engineering. Pharmacol Ther 2005;105:151-63.